Proctor K G, Bealer S L
Circ Res. 1987 Jul;61(1):42-9. doi: 10.1161/01.res.61.1.42.
Synthetic atrial natriuretic factor (ANF) was either added to suffusate solutions (30 nM) or infused into the jugular vein (0.1 nanomol/min/100 g) of anesthetized rats. Steady-state blood flow was calculated from arteriolar diameter and red blood cell velocity measurements using video microscopy in the intestinal or skeletal muscle microcirculation. Arterioles demonstrated spontaneous vasomotor tone by dilating to topical adenosine, but topical or intravenous ANF did not cause vasodilation. Either angiotensin, norepinephrine, or vasopressin was added to the suffusates in the presence or absence of a cyclooxygenase inhibitor (30 microM, meclofenamate or indomethacin) because each agonist is known to stimulate vasoactive prostanoid synthesis. In the intestine, angiotensin (500 nM) caused 40 +/- 2% blood flow decreases during intravenous saline but only 23 +/- 6% during intravenous ANF. Angiotensin (162 nM) and a cyclooxygenase inhibitor caused 19 +/- 4% blood flow decreases but only 8 +/- 5% decreases with cyclooxygenase inhibitor and topical ANF. In contrast, norepinephrine (2-5 microM) caused vasoconstriction that was not altered by topical or intravenous ANF, either alone or in combination with cyclooxygenase inhibitors. In the spinotrapezius muscle, angiotensin (1-2 nM) plus a cyclooxygenase inhibitor caused 40-60% blood flow decreases but only 20-30% decreases during intravenous or topical ANF. Topical or intravenous ANF did not alter the vasoconstriction evoked by arginine vasopressin (0.5-1.0 nM) or by norepinephrine (40-230 nM). Thus, supraphysiologic concentrations of ANF produced no direct vasodilation in the intestinal or skeletal muscle microcirculation.(ABSTRACT TRUNCATED AT 250 WORDS)
将合成的心房利钠因子(ANF)添加到灌注液中(30 nM),或注入麻醉大鼠的颈静脉(0.1纳摩尔/分钟/100克)。使用视频显微镜通过测量小动脉直径和红细胞速度,计算肠道或骨骼肌微循环中的稳态血流。小动脉通过对局部腺苷扩张表现出自发性血管舒缩张力,但局部或静脉注射ANF不会引起血管舒张。在存在或不存在环氧化酶抑制剂(30 microM,甲氯芬那酸或吲哚美辛)的情况下,将血管紧张素、去甲肾上腺素或血管加压素添加到灌注液中,因为已知每种激动剂都会刺激血管活性前列腺素的合成。在肠道中,血管紧张素(500 nM)在静脉注射生理盐水时导致血流减少40±2%,但在静脉注射ANF时仅导致23±6%的减少。血管紧张素(162 nM)和环氧化酶抑制剂导致血流减少19±4%,但在环氧化酶抑制剂和局部ANF存在时仅减少8±5%。相比之下,去甲肾上腺素(2 - 5 microM)引起的血管收缩不受局部或静脉注射ANF单独或与环氧化酶抑制剂联合使用的影响。在斜方肌中,血管紧张素(1 - 2 nM)加环氧化酶抑制剂导致血流减少40 - 60%,但在静脉注射或局部注射ANF时仅减少20 - 30%。局部或静脉注射ANF不会改变精氨酸血管加压素(0.5 - 1.0 nM)或去甲肾上腺素(40 - 230 nM)引起的血管收缩。因此,超生理浓度的ANF在肠道或骨骼肌微循环中不会产生直接的血管舒张作用。(摘要截断于250字)